Product
Recombinant human interleukin-7
Aliases
CYT107
1 clinical trial
2 indications
Indication
Mycobacterial InfectionsIndication
NontuberculousClinical trial
Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease. Two Doses Phase II, Single Center, Open-label TrialStatus: Terminated, Estimated PCD: 2023-12-31